Predictive Diagnostic for Coronary Heart Disease

The oxidised low density lipoprotein (oxLDL) diagnostic test is expected to radically alter the clinical diagnosis of heart attacks in the emergency room setting. Lab 21 has entered into an exclusive license with Ark Therapeutics of a diagnostic test to measure autoantibodies to oxidised low density lipoprotein (oxLDL), which is a predictive risk factor for the development of coronary heart disease (CHD). The oxLDL test can identify those individuals at the greatest risk of developing CHD, allowing for early preventative action.